The complexity of medicines development and urgency to deliver effective patient engagement necessitates a phased working approach to the development of a meta-framework for patient engagement- PFMD’ end goal.
PFMD is taking a rational and methodological approach to co-create a meta-framework with key stakeholders in 4 key steps:
The next step in PFMD’s approach is to create 3 working groups of committed experts and stakeholders. Each Group will focus its efforts on patient engagement at a specific stage of the medicines development pathway.
- Working Group 1: Discovery and Preclinical
- Working Group 2: Phase II, Phase III clinical studies and Regulatory
- Working Group 3: Phase IV clinical studies and lifecycle management (including safety and compliance)
Outputs of the Working Groups will then be integrated in the global patient engagement meta-framework.
Want to find out more? You can contact Chi Pakarinen.